Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI | JACC: Cardiovascular Interventions
JCM | Free Full-Text | Pharmacodynamics and Outcomes of a De-Escalation Strategy with Half-Dose Prasugrel or Ticagrelor in East Asians Patients with Acute Coronary Syndrome: Results from HOPE-TAILOR Trial | HTML
Effects of Crushed Ticagrelor Versus Eptifibatide Bolus Plus Clopidogrel in Troponin‐Negative Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Randomized Clinical Trial | Journal of the American Heart Association
Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI - ScienceDirect
Double (360mg) Loading Dose Of Ticagrelor In Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention | tctmd.com
Transition between ticagrelor and two different doses of clopidogrel at hospital discharge in patients with acute coronary syndrome submitted to percutaneous coronary intervention - ScienceDirect
Figure 1 from Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction. | Semantic Scholar
2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy - Canadian Journal of Cardiology
Antiplatelet therapy in coronary artery disease
Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome Undergoing Complex Percutaneous Coronary Intervention | Circulation: Cardiovascular Interventions
Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD: JACC Review Topic of the Week - ScienceDirect
Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial | Scientific Reports
Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial - The Lancet
Brilinta (Ticagrelor Tablets for Oral Administration): Uses, Dosage, Side Effects, Interactions, Warning
VisualAbstract: Ticagrelor non-superior to clopidogrel in the reduction of PCI-related myocardial necrosis | 2 Minute Medicine
Effectiveness and Safety of Ticagrelor Implementation in Patients with Acute Coronary Syndrome undergoing Percutaneous Coronary Intervention: A Cohort Study in Western Denmark - The Lancet Regional Health – Europe
Transition between ticagrelor and two different doses of clopidogrel at hospital discharge in patients with acute coronary syndrome submitted to percutaneous coronary intervention | Revista Brasileira de Cardiologia Invasiva (English Edition)
JCM | Free Full-Text | De-Escalation of Antiplatelet Treatment in Patients with Myocardial Infarction Who Underwent Percutaneous Coronary Intervention: A Review of the Current Literature | HTML
Ticagrelor and preconditioning in patients with stable coronary artery disease (TAPER-S): a randomized pilot clinical trial | Trials | Full Text
Ticagrelor (Brilinta) for Secondary Prevention of Thrombotic Events Following Acute Coronary Syndrome - STEPS - American Family Physician
Dosing & Administration | BRILINTA® (ticagrelor) tablets | For HCPs
Ticagrelor Dosage Guide + Max Dose, Adjustments - Drugs.com
FIG URE 1 Flow chart of the study. PCI, percutaneous coronary... | Download Scientific Diagram
